-
2023-507695-52-00
5
2021-03-05
Mantle cell lymphoma
-
2024-513730-38-00
5
2021-01-13
Resectable Non-small cell lung cancer
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2023-509358-72-00
5
2020-11-23
Diffuse large B-cell lymphoma
-
2024-514733-38-00
5
2020-11-03
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2022-502084-38-00
5
2020-10-16
Cancer
-
2023-506877-37-00
5
2020-09-28
Relapsed/Refractory Multiple Myeloma
-
2024-516481-11-00
5
2020-09-22
Metastatic Castration-Resistant Prostate Cancer
-
2023-505830-89-00
6
2020-08-05
metastatic castrate resistant prostate cancer (mCRPC)
-
2023-509242-35-00
5
2020-07-23
HR+/HER2- early breast cancer
-
2024-511317-38-00
4
2020-05-04
ALK+ non-small cell lung cancer
-
2023-506783-14-00
5
2020-02-24
Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
-
2024-511747-25-00
4
2019-12-23
B-cell non-Hodgkin lymphoma (NHL)
-
2022-502478-18-00
4
2019-12-20
Acute Myeloid Leukemia (AML)
-
2024-516847-23-00
4
2019-08-27
ER-positive and HER2-negative metastatic or locally advanced breast ca
-
2023-510268-11-00
4
2019-06-11
Cervical cancer
-
2023-507564-39-00
1
2019-03-11
Patients with Advanced Solid Tumors
-
2023-503812-34-00
4
2019-02-13
Locally Advanced or Metastatic Disease in Solid Tumors
-
2022-501485-22-00
5
2018-12-18
Myelodysplastic syndrome (MDS)
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2024-516662-11-00
5
2018-11-23
Ovarian epithelial
cancer
-
2024-516905-22-00
5
2018-10-22
Multiple myeloma
-
2024-510967-41-00
5
2018-09-21
Metastatic colorectal cancer